Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T15:33:45.943Z.
Calculation as of: 2026-10-06T15:33:45.943Z.
Quote observation: 2026-10-06T15:31:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 53f0b653117dfddf80d57e74ba570551200adc0db5709ea8e1a3c029d43ac92d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
MBX Biosciences, Inc. Common Stock
Market Cap
$2.75B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.70B
EV/EBITDA Ratio
9.52x
TTM Avg
8.14x
3Y Avg
8.61x
5Y Avg
8.66x
Market Cap
$2.69B
EV/EBITDA Ratio
13.24x
TTM Avg
11.53x
3Y Avg
20.03x
5Y Avg
19.21x
Market Cap
$2.69B
EV/EBITDA Ratio
32.88x
TTM Avg
28.10x
3Y Avg
22.56x
5Y Avg
30.37x
Market Cap
$2.82B
EV/EBITDA Ratio
27.24x
TTM Avg
35.89x
3Y Avg
85.56x
5Y Avg
85.56x
Market Cap
$2.64B
EV/EBITDA Ratio
N/A
TTM Avg
3.68x
3Y Avg
3.68x
5Y Avg
3.68x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MBX Biosciences, Inc. Common Stock (MBX) | $2.75B | N/A | N/A | N/A | N/A |
| Precigen, Inc. (PGEN)vs › | $2.73B | N/A | N/A | N/A | N/A |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.70B | 9.52x | 8.14x | 8.61x | 8.66x |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.69B | 13.24x | 11.53x | 20.03x | 19.21x |
| Neogen Corporation (NEOG)vs › | $2.69B | 32.88x | 28.10x | 22.56x | 30.37x |
| AtriCure, Inc. (ATRC)vs › | $2.78B | 77.33x | 85.01x | 85.01x | 85.01x |
| Beam Therapeutics Inc. (BEAM)vs › | $2.64B | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.82B | 27.24x | 35.89x | 85.56x | 85.56x |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.64B | N/A | 3.68x | 3.68x | 3.68x |
| Privia Health Group, Inc. (PRVA)vs › | $2.59B | N/A | 70.45x | 91.30x | 141.66x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
